New Directions in the Pharmacological Treatment of Social Disability in ASD

Thursday, May 11, 2017: 2:40 PM-3:30 PM
Yerba Buena 3-6 (Marriott Marquis Hotel)
Moderator:
B. H. King
2:40 PM
113.001
A Randomized Controlled Trial of Riluzole in Autism Spectrum Disorder
R. Nicolson T. Bennett O. Akintan C. Harvey J. A. Brian L. Capano C. Hodgins O. Kraus de Camargo D. Mankad A. Ahmad M. Chalupka L. Colli L. Genore A. Greco T. Lui A. Iaboni I. O'Connor D. Odrobina K. Thorpe E. Anagnostou
2:52 PM
113.002
A Randomized Controlled Trial of Intranasal Oxytocin in Autism Spectrum Disorder
E. Anagnostou J. A. Brian C. Campo-Soria L. Capano A. N. Esler R. Hudock D. Mankad M. Penner S. M. Francis L. Genore A. Iaboni D. Odrobina N. Peleg D. Rambeck E. L. Shankland A. Dupuis S. Jacob
3:04 PM
113.003
Intranasal Vasopressin Treatment Improves Social Abilities in Children with Autism
K. J. Parker O. Oztan R. A. Libove R. D. Sumiyoshi D. S. Karhson J. Summers K. Hinman K. S. Motonaga L. K. Fung D. S. Carson J. M. Phillips J. P. Garner A. Y. Hardan
3:16 PM
113.004
Results of a Phase 2 Randomized Double-Blind Placebo Controlled Study (VANILLA) Investigating the Efficacy and Safety of a V1a Antagonist (RG7314) in Adult Men with ASD
F. Bolognani M. del Valle Rubido L. Squassante C. Wandel X. Liogier D’ardhuy L. Boak M. Derks H. Kletzl S. L. Lennon-Chrimes L. Murtagh J. Noldeke P. Fontoura O. Khwaja D. Umbricht
See more of: Interventions - Pharmacologic
<< Previous Panel | Next Panel >>